Abbott Laboratories (ABT) has been attracting significant attention, with institutions adjusting their stakes in many ways.
Voya Investment Management and
Meadowbrook Wealth Management lowered and acquired their stakes, respectively. The global medical technology company also recently scored some critical startup wins with its
pediatric heart device, potentially a game-changer for their market profile. Significant share purchases by
the Czech National Bank and
Provident Investment Management Inc. bolster investor sentiment towards ABT. In a curious shift, both
TruWealth Advisors and
Union Bancaire Privee sold significant numbers of ABT shares, while
Osaic Holdings and
Insight Wealth Strategies added ABT shares to their portfolio. Relevant news includes the deal with
Exact Sciences whose acquisition by Abbott has been deemed 'very important' by Jim Cramer. However, mixed sentiments are seen on the market, with some questioning Abbott's ABT stock value post the medical device momentum while others, like UBS, maintain a 'Buy' rating. The company has also been consistently named for its potential dividend value, making it a promising candidate for income-focused investment portfolios.
Abbott Laboratories ABT News Analytics from Thu, 17 Jul 2025 07:00:00 GMT to Sat, 20 Dec 2025 13:40:00 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 1
